[EN] THIENOPYRIMIDINE DERIVATIVE AND USE THEREOF IN MEDICINE<br/>[FR] DÉRIVÉ DE THIÉNOPYRIMIDINE ET SON UTILISATION EN MÉDECINE
申请人:SUNSHINE LAKE PHARMA CO LTD
公开号:WO2018133858A1
公开(公告)日:2018-07-26
The present invention relates to a thienopyrimidine derivative and use thereof in medicine, and also to a pharmaceutical composition containing the compound. The compound or pharmaceutical composition is used for inhibiting acetyl-CoA carboxylase (ACC). The present invention also relates to a method of preparing such compound and pharmaceutical composition, as well as their use in the treatment or prevention of diseases regulated by acetyl-CoA carboxylase in mammals, especially in humans.
Regioselective generation of iminium cation by PET processes: Its in situ trapping by intramolecular nucleophiles and synthesis of some biologically active heterocycles.
作者:Ganesh Pandey、G. Kumaraswamy、P.Yella Reddy
DOI:10.1016/s0040-4020(01)80497-x
日期:1992.1
Efficient, mild and direct route for regiospecific iminium cation is developed by sequential two electronoxidation of several N-alkylated tertiary amines by photoinducedelectrontransfer processes. The regiospecificity of iminium cation arises from the deprotonation step of amine radical cation to generate α-amino radical which depends on the stereoelectronic factor subject to kinetic acidity of
Thienopyrimidine derivative and use thereof in medicine
申请人:SUNSHINE LAKE PHARMA CO., LTD.
公开号:US10759812B2
公开(公告)日:2020-09-01
The present invention relates to a thienopyrimidine derivative and use thereof in medicine, and also to a pharmaceutical composition containing the compound. The compound or pharmaceutical composition is used for inhibiting acetyl-CoA carboxylase (ACC). The present invention also relates to a method of preparing such compound and pharmaceutical composition, as well as their use in the treatment or prevention of diseases regulated by acetyl-CoA carboxylase in mammals, especially in humans.
Thienopyrimidine derivatives as ACC inhibitors and uses thereof
申请人:Gilead Sciences, Inc.
公开号:US11352371B2
公开(公告)日:2022-06-07
The present disclosure relates generally to thienopyrimidine compounds that bind to Acetyl-CoA Carboxylase (ACC) and act as inhibitors of ACC. The disclosure further relates to the use of the thienopyrimidine compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of ACC, including liver diseases such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).